Cargando…
Metformin and erlotinib synergize to inhibit basal breast cancer
Basal-like breast cancers (BBCs) are enriched for increased EGFR expression and decreased expression of PTEN. We found that treatment with metformin and erlotinib synergistically induced apoptosis in a subset of BBC cell lines. The drug combination led to enhanced reduction of EGFR, AKT, S6 and 4EBP...
Autores principales: | Lau, Ying-Ka Ingar, Du, Xing, Reyannavar, Vinayak, Hopkins, Benjamin, Shaw, Jacquelyn, Bessler, Eliana, Thomas, Tiffany, Pires, Maira M., Keniry, Megan, Parsons, Ramon E., Cremers, Serge, Szabolcs, Matthias, Maurer, Matthew A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279389/ https://www.ncbi.nlm.nih.gov/pubmed/25361177 |
Ejemplares similares
-
Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
por: Shi, Lingyi, et al.
Publicado: (2017) -
Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
por: Li, Rui, et al.
Publicado: (2013) -
Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression
por: Suárez-Arroyo, Ivette J., et al.
Publicado: (2016) -
Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells
por: Pires, Maira M., et al.
Publicado: (2013) -
Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
por: Wang, Xiaofei, et al.
Publicado: (2017)